Kalvista Pharmaceuticals Inc (KALV)

$26.06 0.95 (3.78%)

16:00 EDT KALV Stock Quote Delayed 30 Minutes

KALV Stock: 8 Things to Know About KalVista Pharmaceuticals as Shares Skyrocket Today

By Nick Clarkson, Web Editor Feb 9, 2021

Shares of KALV stock are blasting off on Tuesday after KalVista Pharmaceuticals reported strong results from its HAE treatment clinical trial.

5 Stocks to Buy Based on Insider Buying

Volume:

Previous Close -

Market Cap 633.47M

PE Ratio -12.29

EPS -2.12

Volume (Avg. Vol.) 150,508

Day's Range 24.67 - 26.20

52-Week Range 9.42 - 45.00

Dividend & Yield N/A (N/A)

KALV Stock Predictions, Articles, and Kalvista Pharmaceuticals Inc News

From the Web

First Week of December 17th Options Trading For KalVista Pharmaceuticals (KALV)

From Market News Video Apr 23, 2021

Investors in KalVista Pharmaceuticals Inc (KALV) saw new options become available this week, for the December 17th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

KalVista Pharmaceuticals Enters Oversold Territory (KALV)

From Market News Video Apr 20, 2021

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

31 Stocks Moving In Tuesday's Mid-Day Session

From Benzinga Apr 20, 2021

Gainers MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD) gained 20.8% to $5.32 after dropping more than 10% on Monday. Takung Art Co., Ltd. (NASDAQ: TKAT) shares surged 18.2% to $21.08...

Why Crispr, KalVista And Syndax Are Moving Today

From Benzinga Apr 20, 2021

CRISPR Therapeutics AG (NASDAQ: CRSP), Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) and KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) were among the early movers in the biopharma...

KalVista Stock Falls After FDA Institutes Clinical Hold On Hereditary Angioedema Trial With KVD824

From Benzinga Apr 20, 2021

Two months after KalVista Pharmaceuticals Inc (NASDAQ: KALV) reported positive Phase 2 results for its lead drug KVD900, an oral therapy meant to stem the...

The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex

From Benzinga Apr 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15) Alexion Pharmaceuticals,...